Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth

Journal of Ovarian Research

Volumn 3, Issue 1, 2010, Pages

  Yallapu, Murali M ^a   Maher, Diane M ^a   Sundram, Vasudha ^a   Bell, Maria C ^b   Jaggi, Meena ^a,b   Chauhan, Subhash C ^a,b  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; APOPTOSIS REGULATORY PROTEIN; BETA CATENIN; CASPASE 9; CISPLATIN; CURCUMIN; LUCIFERASE; MONOCLONAL ANTIBODY; NANOPARTICLE; POLYGLACTIN;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CELL VIABILITY; CHEMOSENSITIZATION; DOWN REGULATION; DRUG CONJUGATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO STUDY; LIGHT SCATTERING; OVARY CANCER; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIZATION; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

EID: 77953406082     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-3-11     Document Type: Article

References (53)

1. Cancer statistics, 2009. A Jemal R Siegel E Ward Y Hao J Xu MJ Thun, CA Cancer J Clin 2009 59 225 249 10.3322/caac.20006 19474385
2. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. DK Armstrong, Oncologist 2002 7 Suppl 5 20 28 10.1634/theoncologist.7-suppl-5-20 12324630
3. Pharmaceutical management of ovarian cancer: current status. M Markman, Drugs 2008 68 771 789 10.2165/00003495-200868060-00004 18416585
4. Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials. M Markman K Webster K Zanotti G Peterson B Kulp J Belinson, Gynecol Oncol 2004 93 699 701 10.1016/j.ygyno.2004.03.023 15196867
5. How do real tumors become resistant to cisplatin? P Borst S Rottenberg J Jonkers, Cell Cycle 2008 7 1353 1359 18418074
6. Ovarian cancer: a focus on management of recurrent disease. TJ Herzog B Pothuri, Nat Clin Pract Oncol 2006 3 604 611 10.1038/ncponc0637 17080178
7. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. RD Alvarez WK Huh MB Khazaeli RF Meredith EE Partridge LC Kilgore WE Grizzle S Shen JM Austin MN Barnes,, et al. Clin Cancer Res 2002 8 2806 2811 12231520
8. Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer. RF Meredith DJ Buchsbaum RD Alvarez AF LoBuglio, Clin Cancer Res 2007 13 5643s 5645s 10.1158/1078-0432. CCR-07-0985 17875801
9. Curcumin and Quercetin Combined with Cisplatin to Induce Apoptosis in Human Laryngeal Carcinoma Hep-2 Cells through the Mitochondrial Pathway. SI Meenakshi Kuhar Singh Neeta, Journal of Cancer Molecules 2007 3 121 128
10. Combined xanthorrhizol-curcumin exhibits synergistic growth inhibitory activity via apoptosis induction in human breast cancer cells MDA-MB-231. YH Cheah FJ Nordin R Sarip TT Tee HL Azimahtol HM Sirat BA Rashid NR Abdullah Z Ismail, Cancer Cell Int 2009 9 1 10.1186/1475-2867-9-1 19118501
11. Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. IA Siddiqui A Malik VM Adhami M Asim BB Hafeez S Sarfaraz H Mukhtar, Oncogene 2008 27 2055 2063 10.1038/sj.onc.1210840 17998943
12. Review of Curcumin Effects on Signaling Pathways in Cancer. SCC Bal Krishnan Jaggi Meena Jaggi, Proceedings of the South Dakota Academy of Science 2007 86 283 293
13. Curcumin activated both receptor-mediated and mitochondria-mediated proteolytic pathways for apoptosis in human glioblastoma T98G cells. S Karmakar NL Banik SJ Patel SK Ray, Neurosci Lett 2006 407 53 58 10.1016/j.neulet.2006.08. 013 16949208
14. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. S Shishodia HM Amin R Lai BB Aggarwal, Biochem Pharmacol 2005 70 700 713 10.1016/j.bcp.2005.04.043 16023083
15. Role of curcumin in cancer therapy. S Shishodia MM Chaturvedi BB Aggarwal, Curr Probl Cancer 2007 31 243 305 10.1016/j.currproblcancer.2007.04. 001 17645940
16. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. AL Cheng CH Hsu JK Lin MM Hsu YF Ho TS Shen JY Ko JT Lin BR Lin W Ming-Shiang,, et al. Anticancer Res 2001 21 2895 2900 11712783
17. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. G Garcea DJ Jones R Singh AR Dennison PB Farmer RA Sharma WP Steward AJ Gescher DP Berry, Br J Cancer 2004 90 1011 1015 10.1038/sj.bjc.6601623 14997198
18. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. K Hamaguchi AK Godwin M Yakushiji PJ O'Dwyer RF Ozols TC Hamilton, Cancer Res 1993 53 5225 5232 8106143
19. Expression and functions of transmembrane mucin MUC13 in ovarian cancer. SC Chauhan K Vannatta MC Ebeling N Vinayek A Watanabe KK Pandey MC Bell MD Koch H Aburatani Y Lio M Jaggi, Cancer Res 2009 69 765 774 10.1158/0008-5472.CAN-08- 0587 19176398
20. Bryostatin 1 modulates beta-catenin subcellular localization and transcription activity through protein kinase D1 activation. M Jaggi SC Chauhan C Du KC Balaji, Mol Cancer Ther 2008 7 2703 2712 10.1158/1535-7163.MCT-08-0119 18765827
21. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. T Govender S Stolnik MC Garnett L Illum SS Davis, J Control Release 1999 57 171 185 10.1016/S0168-3659(98)00116-3 9971898
22. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. S Bisht G Feldmann S Soni R Ravi C Karikar A Maitra A Maitra, J Nanobiotechnology 2007 5 3 10.1186/1477-3155-5-3 17439648
23. Fluorescently labeled cellulose nanocrystals for bioimaging applications. S Dong M Roman, J Am Chem Soc 2007 129 13810 13811 10.1021/ja076196l 17949004
24. beta-Catenin signaling in biological control and cancer. N Gavert A Ben-Ze'ev, J Cell Biochem 2007 102 820 828 10.1002/jcb.21505 17854061
25. Cadherin-mediated cellular signaling. MJ Wheelock KR Johnson, Curr Opin Cell Biol 2003 15 509 514 10.1016/S0955-0674(03)00101-7 14519384
26. Wnt signaling in ovarian tumorigenesis. TA Gatcliffe BJ Monk K Planutis RF Holcombe, Int J Gynecol Cancer 2008 18 954 962 10.1111/j.1525-1438.2007. 01127.x 17986238
27. Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. D Sarrio G Moreno-Bueno C Sanchez-Estevez I Banon-Rodriguez G Hernandez-Cortes D Hardisson J Palacios, Hum Pathol 2006 37 1042 1049 10.1016/j.humpath.2006.03.003 16867867
28. Wnt signaling inhibits Forkhead box O3a-induced transcription and apoptosis through up-regulation of serum- and glucocorticoid-inducible kinase 1. M Dehner M Hadjihannas J Weiske O Huber J Behrens, J Biol Chem 2008 283 19201 19210 10.1074/jbc.M710366200 18487207
29. Identification of genes regulated by Wnt/beta-catenin pathway and involved in apoptosis via microarray analysis. M Huang Y Wang D Sun H Zhu Y Yin W Zhang S Yang L Quan J Bai S Wang,, et al. BMC Cancer 2006 6 221 10.1186/1471-2407-6-221 16959035
30. Wnt/beta-catenin signaling inhibits death receptor-mediated apoptosis and promotes invasive growth of HNSCC. F Yang Q Zeng G Yu S Li CY Wang, Cell Signal 2006 18 679 687 10.1016/j.cellsig.2005.06.015 16084063
31. EB1 acts as an oncogene via activating beta-catenin/TCF pathway to promote cellular growth and inhibit apoptosis. M Liu S Yang Y Wang H Zhu S Yan W Zhang L Quan J Bai N Xu, Mol Carcinog 2009 48 212 219 10.1002/mc.20471 18680107
32. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. P Anand HB Nair B Sung AB Kunnumakkara VR Yadav RR Tekmal BB Aggarwal, Biochem Pharmacol 2010 79 330 338 10.1016/j.bcp.2009.09.003 19735646
33. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. J Shaikh DD Ankola V Beniwal D Singh MN Kumar, Eur J Pharm Sci 2009 37 223 230 10.1016/j.ejps.2009.02.019 19491009
34. Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis. MP Ponnusamy G Venkatraman AP Singh SC Chauhan SL Johansson M Jain L Smith JS Davis SW Remmenga SK Batra, Cancer Lett 2007 251 247 257 10.1016/j.canlet.2006.11.025 17210225
35. Microtubule active agents: beyond the taxane frontier. PG Morris MN Fornier, Clin Cancer Res 2008 14 7167 7172 10.1158/1078-0432.CCR-08-0169 19010832
36. Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. EA Perez, Breast Cancer Res Treat 2009 114 195 201 10.1007/s10549-008-0005-6 18443902
37. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. R Krishna LD Mayer, Eur J Pharm Sci 2000 11 265 283 10.1016/S0928-0987(00)00114-7 11033070
38. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. D Chendil RS Ranga D Meigooni S Sathishkumar MM Ahmed, Oncogene 2004 23 1599 1607 10.1038/sj.onc.1207284 14985701
39. The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway. P Javvadi AT Segan SW Tuttle C Koumenis, Mol Pharmacol 2008 73 1491 1501 10.1124/mol.107. 043554 18252805
40. Inhibition of growth and sensitization to cisplatin-mediated killing of ovarian cancer cells by polyphenolic chemopreventive agents. MM Chan D Fong KJ Soprano WF Holmes H Heverling, J Cell Physiol 2003 194 63 70 10.1002/jcp.10186 12447990
41. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. D Chirnomas T Taniguchi M de la Vega AP Vaidya M Vasserman AR Hartman R Kennedy R Foster J Mahoney MV Seiden AD D'Andrea, Mol Cancer Ther 2006 5 952 961 10.1158/1535-7163.MCT-05-0493 16648566
42. Cell-cycle inhibition and apoptosis induced by curcumin and cisplatin or oxaliplatin in human ovarian carcinoma cells. M Montopoli E Ragazzi G Froldi L Caparrotta, Cell Prolif 2009 42 195 206 10.1111/j.1365-2184.2009.00585.x 19236381
43. Bcl2 family proteins in carcinogenesis and the treatment of cancer. A Frenzel F Grespi W Chmelewskij A Villunger, Apoptosis 2009 14 584 596 10.1007/s10495-008-0300-z 19156528
44. Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. M Lopez-Lazaro, Mol Nutr Food Res 2008 52 Suppl 1 103 127 18496811
45. Clinical studies with curcumin. CH Hsu AL Cheng, Adv Exp Med Biol 2007 595 471 480 full-text 17569225
46. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. RA Sharma SA Euden SL Platton DN Cooke A Shafayat HR Hewitt TH Marczylo B Morgan D Hemingway SM Plummer,, et al. Clin Cancer Res 2004 10 6847 6854 10.1158/1078-0432.CCR-04-0744 15501961
47. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. C Ireson S Orr DJ Jones R Verschoyle CK Lim JL Luo L Howells S Plummer R Jukes M Williams,, et al. Cancer Res 2001 61 1058 1064 11221833
48. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. CR Ireson DJ Jones S Orr MW Coughtrie DJ Boocock ML Williams PB Farmer WP Steward AJ Gescher, Cancer Epidemiol Biomarkers Prev 2002 11 105 111 11815407
49. Nanoparticle-based targeted drug delivery. R Singh JW Lillard Jr, Exp Mol Pathol 2009 86 215 223 10.1016/j.yexmp.2008.12.004 19186176
50. Targeted nanoparticle-based drug delivery and diagnosis. DF Emerich CG Thanos, J Drug Target 2007 15 163 183 10.1080/10611860701231810 17454354
51. Active targeting schemes for nanoparticle systems in cancer therapeutics. JD Byrne T Betancourt L Brannon-Peppas, Adv Drug Deliv Rev 2008 60 1615 1626 10.1016/j.addr.2008.08.005 18840489
52. Nanoparticle therapeutics: an emerging treatment modality for cancer. ME Davis ZG Chen DM Shin, Nat Rev Drug Discov 2008 7 771 782 10.1038/nrd2614 18758474
53. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. JF Kukowska-Latallo KA Candido Z Cao SS Nigavekar IJ Majoros TP Thomas LP Balogh MK Khan JR Baker Jr, Cancer Res 2005 65 5317 5324 10.1158/0008-5472.CAN-04-3921 15958579